Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PENTOXIFYLLINE FOR TREATMENT OF CANCER ANOREXIA AND CACHEXIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Autore:
GOLDBERG RM; LOPRINZI CL; MAILLIARD JA; OFALLON JR; KROOK JE; GHOSH C; HESTORFF RD; CHONG SF; REUTER NF; SHANAHAN TG;
Indirizzi:
MAYO CLIN & MAYO FDN,DEPT ONCOL,200 1ST ST SW ROCHESTER MN 55905 DULUTH COMMUNITY CLIN ONCOL PROGRAM DULUTH MN 00000 ST CLOUD CLIN INTERNAL MED LTD ST CLOUD MN 00000 CREIGHTON UNIV,UNIV NEBRASKA MED CTR & ASSOCIATES,NEBRASKA ONCOL GRP OMAHA NE 00000 CEDAR RAPIDS ONCOL PROJECT COMMUNITY,CLIN ONCOL PROGRAM CEDAR RAPIDS IA 00000 GRAND FORKS CLIN LTD GRAND FORKS ND 00000 CARLE CANC CTR COMMUNITY,CLIN ONCOL PROGRAM URBANA IL 00000
Titolo Testata:
Journal of clinical oncology
fascicolo: 11, volume: 13, anno: 1995,
pagine: 2856 - 2859
SICI:
0732-183X(1995)13:11<2856:PFTOCA>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; MEGESTROL-ACETATE; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
17
Recensione:
Indirizzi per estratti:
Citazione:
R.M. Goldberg et al., "PENTOXIFYLLINE FOR TREATMENT OF CANCER ANOREXIA AND CACHEXIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL", Journal of clinical oncology, 13(11), 1995, pp. 2856-2859

Abstract

Purpose: Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicityof this drug in patients with cancer-associated anorexia and/or cachexia. Patients and Methods: Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of greater than or equalto 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d)were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. Results: Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. Conclusion: This study failedto demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia. (C) 1995 by AmericanSociety of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 08:21:17